CPP-115, a vigabatrin analogue, decreases spasms in the multiple-hit rat model of infantile spasms

Epilepsia

Volumn 55, Issue 1, 2014, Pages 94-102

  Briggs, Stephen W ^a   Mowrey, Wenzhu ^a   Hall, Charles B ^a   Galanopoulou, Aristea S ^a,b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

Doxorubicin; Epilepsy; GABA aminotransferase; Learning; Lipopolysaccharide; Memory; Neurodevelopmental reflexes; Seizure

Indexed keywords

CPP 115; UNCLASSIFIED DRUG; VIGABATRIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BARNES MAZE TEST; BODY WEIGHT; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG TOLERABILITY; ELECTROENCEPHALOGRAM; ELECTROENCEPHALOGRAPHY; EXPERIMENTAL BEHAVIORAL TEST; INFANT; INFANTILE SPASM; LEARNING; MALE; NERVE CELL DIFFERENTIATION; NONHUMAN; OPEN FIELD BEHAVIOR; OPEN FIELD TEST; PRIORITY JOURNAL; RAT; RIGHTING REFLEX; RIGHTING REFLEX TEST; SINGLE DRUG DOSE; SURVIVAL; TREATMENT OUTCOME; VIDEORECORDING; WEIGHT GAIN;

DOXORUBICIN; EPILEPSY; GABA AMINOTRANSFERASE; LEARNING; LIPOPOLYSACCHARIDE; MEMORY; NEURODEVELOPMENTAL REFLEXES; SEIZURE;

ANIMALS; ANIMALS, NEWBORN; ANTICONVULSANTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INFANT; MALE; MAZE LEARNING; MONITORING, PHYSIOLOGIC; PROLINE; RATS; SPASMS, INFANTILE;

EID: 84892923718     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/epi.12424     Document Type: Article

References (38)

1. Hrachovy RA, Frost JD Jr,. Infantile epileptic encephalopathy with hypsarrhythmia (infantile spasms/West syndrome). J Clin Neurophysiol 2003; 20: 408-425.
2. Scantlebury MH, Galanopoulou AS, Chudomelova L, et al. A model of symptomatic infantile spasms syndrome. Neurobiol Dis 2010; 37: 604-612.
3. Mackay MT, Weiss SK, Adams-Webber T, et al. Practice parameter: medical treatment of infantile spasms: report of the American Academy of Neurology and the Child Neurology Society. Neurology 2004; 62: 1668-1681.
4. Pellock JM, Hrachovy R, Shinnar S, et al. Infantile spasms: a U.S. consensus report. Epilepsia 2010; 51: 2175-2189.
5. Go CY, Mackay MT, Weiss SK, et al. Evidence-based guideline update: medical treatment of infantile spasms. Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2012; 78: 1974-1980.
6. Tolman JA, Faulkner MA,. Vigabatrin: a comprehensive review of drug properties including clinical updates following recent FDA approval. Expert Opin Pharmacother 2009; 10: 3077-3089.
7. Lerner JT, Salamon N, Sankar R,. Clinical profile of vigabatrin as monotherapy for treatment of infantile spasms. Neuropsychiatr Dis Treat 2010; 6: 731-740.
8. Jambaque I, Chiron C, Dumas C, et al. Mental and behavioural outcome of infantile epilepsy treated by vigabatrin in tuberous sclerosis patients. Epilepsy Res 2000; 38: 151-160.
9. Carmant L,. Vigabatrin therapy for infantile spasms: review of major trials in Europe, Canada, and the United States; and recommendations for dosing. Acta Neurol Scand Suppl 2011; 192: 36-47.
10. Eke T, Talbot JF, Lawden MC,. Severe persistent visual field constriction associated with vigabatrin. BMJ 1997; 314: 180-181.
11. Krauss GL, Johnson MA, Miller NR,. Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings. Neurology 1998; 50: 614-618.
12. John RA, Rimmer EM, Williams J, et al. Micro-vacuolation in rat brains after long term administration of GABA-transaminase inhibitors. Comparison of effects of ethanolamine-O-sulphate and vigabatrin. Biochem Pharmacol 1987; 36: 1467-1473.
13. Hammond EJ, Ballinger WE Jr, Lu L, et al. Absence of cortical white matter changes in three patients undergoing long-term vigabatrin therapy. Epilepsy Res 1992; 12: 261-265.
14. Agosti R, Yasargil G, Egli M, et al. Neuropathology of a human hippocampus following long-term treatment with vigabatrin: lack of microvacuoles. Epilepsy Res 1990; 6: 166-170.
15. Horton M, Rafay M, Del Bigio MR,. Pathological evidence of vacuolar myelinopathy in a child following vigabatrin administration. J Child Neurol 2009; 24: 1543-1546.
16. Pan Y, Gerasimov MR, Kvist T, et al. (1S, 3S)-3-amino-4- difluoromethylenyl-1-cyclopentanoic acid (CPP-115), a potent gamma-aminobutyric acid aminotransferase inactivator for the treatment of cocaine addiction. J Med Chem 2012; 55: 357-366.
17. Pan Y, Qiu J, Silverman RB,. Design, synthesis, and biological activity of a difluoro-substituted, conformationally rigid vigabatrin analogue as a potent gamma-aminobutyric acid aminotransferase inhibitor. J Med Chem 2003; 46: 5292-5293.
18. Silverman RB,. The 2011 E. B. Hershberg award for important discoveries in medicinally active substances: (1S,3S)-3-amino-4-difluoromethylenyl-1- cyclopentanoic acid (CPP-115), a GABA aminotransferase inactivator and new treatment for drug addiction and infantile spasms. J Med Chem 2012; 55: 567-575.
19. Ono T, Moshe SL, Galanopoulou AS,. Carisbamate acutely suppresses spasms in a rat model of symptomatic infantile spasms. Epilepsia 2011; 52: 1678-1684.
20. Raffo E, Coppola A, Ono T, et al. A pulse rapamycin therapy for infantile spasms and associated cognitive decline. Neurobiol Dis 2011; 43: 322-329.
21. Danglot L, Triller A, Marty S,. The development of hippocampal interneurons in rodents. Hippocampus 2006; 16: 1032-1060.
22. Balcar VJ, Zetzsche T, Wolff JR,. Glutamate decarboxylase in developing rat neocortex: does it correlate with the differentiation of GABAergic neurons and synapses? Neurochem Res 1992; 17: 253-260.
23. Wong PT, McGeer EG,. Postnatal changes of GABAergic and glutamatergic parameters. Brain Res 1981; 227: 519-529.
24. Kristt DA, Waldman JV,. Late postnatal changes in rat somatosensory cortex. Temporal and spatial relationships of GABA-T and AChE histochemical reactivity. Anat Embryol (Berl) 1986; 174: 115-122.
25. Gale K, Iadarola MJ,. Seizure protection and increased nerve-terminal GABA: delayed effects of GABA transaminase inhibition. Science 1980; 208: 288-291.
26. Maguire MJ, Hemming K, Wild JM, et al. Prevalence of visual field loss following exposure to vigabatrin therapy: a systematic review. Epilepsia 2010; 51: 2423-2431.
27. Gaily E, Jonsson H, Lappi M,. Visual fields at school-age in children treated with vigabatrin in infancy. Epilepsia 2009; 50: 206-216.
28. Camposano SE, Major P, Halpern E, et al. Vigabatrin in the treatment of childhood epilepsy: a retrospective chart review of efficacy and safety profile. Epilepsia 2008; 49: 1186-1191.
29. Heim MK, Gidal BE,. Vigabatrin-associated retinal damage: potential biochemical mechanisms. Acta Neurol Scand 2012; 126: 219-228.
30. Izumi Y, Ishikawa M, Benz AM, et al. Acute vigabatrin retinotoxicity in albino rats depends on light but not GABA. Epilepsia 2004; 45: 1043-1048.
31. Jammoul F, Wang Q, Nabbout R, et al. Taurine deficiency is a cause of vigabatrin-induced retinal phototoxicity. Ann Neurol 2009; 65: 98-107.
32. Wild JM, Chiron C, Ahn H, et al. Visual field loss in patients with refractory partial epilepsy treated with vigabatrin: final results from an open-label, observational, multicentre study. CNS Drugs 2009; 23: 965-982.
33. Darke K, Edwards SW, Hancock E, et al. Developmental and epilepsy outcomes at age 4 years in the UKISS trial comparing hormonal treatments to vigabatrin for infantile spasms: a multi-centre randomised trial. Arch Dis Child 2010; 95: 382-386.
34. Lux AL, Edwards SW, Hancock E, et al. The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial. Lancet Neurol 2005; 4: 712-717.
35. Rundfeldt C, Loscher W,. Development of tolerance to the anticonvulsant effect of vigabatrin in amygdala-kindled rats. Eur J Pharmacol 1992; 213: 351-366.
36. Galanopoulou AS,. Sexually dimorphic expression of KCC2 and GABA function. Epilepsy Res 2008; 80: 99-113.
37. Galanopoulou AS, Kokaia M, Loeb JA, et al. Epilepsy therapy development: Technical and methodologic issues in studies with animal models. Epilepsia 2013; 54 (Suppl. 4): 13-23.
38. Galanopoulou AS,. Basic mechanisms of catastrophic epilepsy-overview from animal models. Brain Dev 2013; 35: 748-756.